Aquinox Pharmaceuticals, Inc. (AQXP) Releases Quarterly Earnings Results, Hits Expectations
Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) posted its earnings results on Tuesday. The company reported ($0.59) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.59), MarketWatch Earnings reports.
Shares of Aquinox Pharmaceuticals (NASDAQ AQXP) opened at 14.26 on Wednesday. The firm’s 50-day moving average price is $14.56 and its 200 day moving average price is $15.60. The company’s market capitalization is $334.01 million. Aquinox Pharmaceuticals has a 52-week low of $8.36 and a 52-week high of $19.97.
TRADEMARK VIOLATION WARNING: This article was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/08/09/aquinox-pharmaceuticals-inc-aqxp-releases-quarterly-earnings-results-hits-expectations.html.
Several research firms recently issued reports on AQXP. BidaskClub raised Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 4th. Zacks Investment Research raised Aquinox Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a research note on Thursday, May 11th. Canaccord Genuity set a $22.00 target price on Aquinox Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday. Cantor Fitzgerald set a $28.00 target price on Aquinox Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, May 9th. Finally, ValuEngine raised Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $22.50.
In other news, insider David Main sold 15,625 shares of the stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $13.26, for a total transaction of $207,187.50. Following the transaction, the insider now directly owns 77,530 shares in the company, valued at $1,028,047.80. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 2.70% of the stock is currently owned by company insiders.
Several institutional investors have recently added to or reduced their stakes in the stock. Alps Advisors Inc. increased its stake in shares of Aquinox Pharmaceuticals by 4.7% in the second quarter. Alps Advisors Inc. now owns 21,090 shares of the company’s stock valued at $297,000 after buying an additional 939 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Aquinox Pharmaceuticals by 16.5% in the second quarter. Bank of New York Mellon Corp now owns 23,260 shares of the company’s stock valued at $327,000 after buying an additional 3,299 shares during the period. Archon Partners LLC increased its stake in shares of Aquinox Pharmaceuticals by 44.0% in the second quarter. Archon Partners LLC now owns 18,000 shares of the company’s stock valued at $253,000 after buying an additional 5,500 shares during the period. Investment Centers of America Inc. purchased a new stake in shares of Aquinox Pharmaceuticals during the first quarter valued at $172,000. Finally, Geode Capital Management LLC increased its stake in shares of Aquinox Pharmaceuticals by 10.0% in the first quarter. Geode Capital Management LLC now owns 121,532 shares of the company’s stock valued at $2,028,000 after buying an additional 11,035 shares during the period. Hedge funds and other institutional investors own 98.32% of the company’s stock.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.